This has been such a management failure. It is the only massive mistake that Anavex made and continues to make: failing to run the correct number of trials that are properly powered. It is so shocking that, 18 months after opening acknowledging this shortcoming at the ASM in 2024, they STILL fail to correct this behavior. I am unhappy that this company has such incredibly good therapeutic assets but they squander their opportunities to capitalize on them. SMH.
Market Data 
Markets 
AI
